Presympto, Inc.

Presympto is an early stage company focused on the development of a simple, accurate and cost-effective blood-based diagnostic that will create the ability to test asymptomatic people for Alzheimer's disease—before they have the signs of the disease.

"The scientific community and the FDA believe it is critical to identify and study patients with very early Alzheimer's disease before there is too much irreversible injury to the brain. It is in this population that most researchers believe new drugs have the best chance of providing meaningful benefit to patients."

– Russell Katz, MD, Director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research



AMYLOID BETA PEPTIDE

Presympto has a strong intellectual property position including a core technology patent that describes a method for detecting misfolded proteinaceous particles comprised of predominantly beta-sheet secondary structure. Some of the patents in our portfolio include:

- *Misfolded protein sensor method in body fluids: US 7,166,471*
- *Misfolded protein sensor method: US 8,062,895*
- *Method of detecting misfolded proteins and prions: US 8,372,593*
- *Peptide probes for diagnostics and therapeutics: US 8,673,579*
- *Stabilized amyloid-beta oligomers and uses thereof: US 9,556,247*
- *Conformationally dynamic peptide probes: US 9,696,316*
- *Ocular detection of amyloid proteins: US 9,795,692*
- *Methods for detecting amyloid-beta oligomers US Pat App 20160169913*

Pronucleon™ is a Presympto platform technology using custom-synthesized peptides that allow signal amplification to detect and map the surface of rare proteins. Unlike our platform, recognition molecules used in currently available diagnostic assays for amyloid proteins (e.g. antibodies, aptamers) are not particularly sensitive to protein conformational state. We have created peptides specific for detection of oligomer and fibrillar forms of Aβ. Using unique technology that detects the sequence and the conformation of amyloid proteins, our goal is to create sensitive and specific detection methods that allow early stage diagnosis and disease progression monitoring.

Contact:

Richard O. Cliff, CEO : rcliff@presympto.com : 703-868-3050 : Ridge, MD USA